WALTHAM, Mass.--(BUSINESS WIRE)--Xilio Therapeutics, a biotechnology company developing potent, tumor-selective immunotherapies for patients with cancer, today announced the upcoming presentation of two abstracts featuring preclinical data related to its most advanced product candidates, XTX101 and XTX201. The data will be shared at the 35th Annual Meeting of The Society for Immunotherapy of Cancer (SITC 2020) taking place virtually November 9 – 14, 2020.
The abstract featuring data on XTX201, Xilio’s tumor-selective IL-2, will be shared in a virtual poster viewing session. The abstract featuring data on the tumor-selective aCTLA4 antibody XTX101 will be shared in an oral presentation and in a virtual poster viewing session.
Details on Xilio’s abstracts are as follows:
Abstract #: 568
Abstract Title: XTX201, a protein-engineered IL-2, exhibits tumor-selective activity in mice without peripheral toxicities in non-human primates
Presenting Author: Minjie Zhang, PhD, Senior Scientist, In Vivo Pharmacology at Xilio Therapeutics
Virtual Poster Viewing Session: Thursday, November 12, from 4:50-5:20 p.m. EST and Saturday, November 14, from 1:00-1:30 p.m. EST
Abstract #: 587
Abstract Title: Tumor-activated Fc-engineered anti-CTLA-4 monoclonal antibody, XTX101, demonstrates tumor-selective PD and efficacy in preclinical models
Presenting Oral Presentation Author: Friday November 13, from 4:25-4:40 p.m. EST. Kurt Jenkins, PhD, Principal Scientist, Cell Pharmacology at Xilio Therapeutics
Oral Presentation: Wednesday, November 11, from 5:15-5:45 p.m. EST and Friday, November 13, from 4:40-5:10 p.m. EST
Presenting Poster Session Author: Parker Johnson, PhD, Senior Scientist, Structural Biology at Xilio Therapeutics
Virtual Presentation Viewing Session: Wednesday, November 11, from 5:15-5:45 p.m. EST and Friday, November 13, from 4:40-5:10 p.m. EST
Abstracts can be accessed on the SITC website once the conference begins on November 9 at 8:00 a.m. EST.
About Xilio Therapeutics
Xilio Therapeutics is a biotechnology company that uses its proprietary technology to develop next-generation cancer immunotherapies. Our product candidates are engineered to unleash the power of the immune system selectively at the site of the tumor. Thus, we have designed them to maximize efficacy while overcoming the significant toxicities associated with clinically validated immuno-oncology (IO) therapies, such as IL-2 and anti-CTLA4. The broad applicability of these therapies across cancer types means that a significant number of patients could benefit from these potentially curative medicines.
Xilio was founded in 2016 and is headquartered in Waltham, Mass. For more information, please visit www.xiliotx.com.